News NICE delivers more good news for cervical cancer patients Hundreds of women with locally advanced cervical cancer are to be offered MSD's Keytruda on the NHS in England, thanks to new NICE guidance.
News Ionis' Tryngolza claims critical label expansion in US Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.
News Lilly launches LillyDirect in the UK Eli Lilly's LillyDirect, an important driver of sales of its weight-loss drugs in the US, has now arrived in the UK – with modifications.
News NICE says Libtayo can be used for advanced cervical cancer New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.
News Bispecific antibody firm Ollin raises $330m in bumper round Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.
News Astellas' Padcev and Gilead's Trodelvy grab key EU approvals New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.